Simulation Finds BRAF-Informed TI-RADS Reclassification Could Cut Thyroid Biopsy Recommendations by 14.5%

A simulation of 4944 thyroid nodules found that assuming BRAFV600E status known pre-biopsy, reclassifying TI-RADS reduced FNA recommendations by 14.5% (500 fewer), retaining 96.0% of Bethesda V/VI malignant nodules.

• In the surgical pathology subgroup, malignant nodule retention was 96.4% (95% CI 92.8–98.6%), the lower bound falling below a 95% benchmark, signaling potential missed cancers.
• A patient-grouped random forest model achieved an AUC of only 0.693 (95% CI 0.678–0.707) for pre-FNA prediction, and after calibration reduced biopsy recommendations by 10.6% with retention of 95.6% of Bethesda V/VI nodules.
• Limitation: This simulation used a cohort enriched for BRAFV600E positivity and TI-RADS 4C; prospective evaluation in an unselected pre-biopsy population is required.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.